Story perspectives

Forskolin Boosts Leukemia Treatment Effectiveness, Study Finds

11/28/2025

36 5

Summary

Story summary

A University of Surrey-led study shows forskolin, a natural compound, may enhance treatment for KMT2A-rearranged Acute Myeloid Leukemia (KMT2A-r AML).
Forskolin slows leukemia cell growth and boosts daunorubicin effectiveness.
It activates Protein Phosphatase 2A (PP2A) and reduces cancer-promoting gene activity.
Additionally, forskolin interferes with P-glycoprotein 1, allowing higher daunorubicin concentrations in leukemia cells.
The study was supported by Leukaemia UK and involved multiple research institutions.

1 of 1

Story summary

A University of Surrey-led study shows forskolin, a natural compound, may enhance treatment for KMT2A-rearranged Acute Myeloid Leukemia (KMT2A-r AML).
Forskolin slows leukemia cell growth and boosts daunorubicin effectiveness.
It activates Protein Phosphatase 2A (PP2A) and reduces cancer-promoting gene activity.
Additionally, forskolin interferes with P-glycoprotein 1, allowing higher daunorubicin concentrations in leukemia cells.
The study was supported by Leukaemia UK and involved multiple research institutions.